Endeavour Asset Management provided an update a few weeks ago for January. They had this to say about MVP:
"Acute non-opioid pain relief provider Medical Developments ($700m market capitalisation) continued its upward trajectory, rising 14% in January following on from the 73% rally in the December quarter. Medical Developments has been a core long term holding and it is pleasing to see that our patience is being rewarded.
In October, Penthrox was included in European Society Emergency Medicine guidelines as first line treatment for moderate to severe Trauma pain following studies demonstrating superiority of Penthroxover current standard of care drugs. This supports our investment thesis for the long-term adoption of Penthrox not only in Europe but globally which is the key value driver for the company. In the December quarter, Medical Developments made good progress towards approval for Penthrox in key large target markets Russia and China. "
MVP Price at posting:
$8.19 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)